When administered as standard three-dose schedules, the licensed HPV prophylactic vaccines have demonstrated extraordinary immunogenicity and efficacy. We summarize the immunogenicity of these licensed vaccines and the most commonly used serology assays, with a focus on key considerations for one-dose vaccine schedules.
Although immune correlates of protection against infection are not entirely clear, both preclinical and clinical evidence point to neutralizing antibodies as the principal mechanism of protection. Thus, immunogenicity assessments in vaccine trials have focused on measurements of antibody responses to the vaccine. Non-inferiority of antibody responses after two doses of HPV vaccines separated by 6 months has been demonstrated and this evidence supported the recent WHO recommendations for two-dose vaccination schedules in both boys and girls 9–14 years of age. There is also some evidence suggesting that one dose of HPV vaccines may provide protection similar to the currently recommended two-dose regimens but robust data on efficacy and immunogenicity of one-dose vaccine schedules are lacking. In addition, immunogenicity has been assessed and reported using different methods, precluding direct comparison of results between different studies and vaccines. New head-to-head vaccine trials evaluating one-dose immunogenicity and efficacy have been initiated and an increase in the number of trials relying on immunobridging is anticipated. Therefore, standardized measurement and reporting of immunogenicity for the up to nine HPV types targeted by the current vaccines is now critical. Building on previous HPV serology assay standardization and harmonization efforts initiated by the WHO HPV LabNet in 2006, new secondary standards, critical reference reagents and testing guidelines will be generated as part of a new partnership to facilitate harmonization of the immunogenicity testing in new HPV vaccine trials.
There are currently three licensed HPV prophylactic vaccines: Cervarix®, a bivalent HPV-16/18 product from GlaxoSmithKline; Gardasil®, a quadrivalent HPV-6/11/16/18 product and Gardasil®9, a nonavalent HPV-6/11/16/18/31/33/45/52/58 vaccine, both from Merck & Co., Inc. [1], [2], [3], [4]. These products were licensed following highly encouraging efficacy data from large phase III vaccine trials and have the potential (nonavalent vaccine) to prevent up to 90% of cervical cancer cases. The first two products to be licensed, Cervarix® and Gardasil®, used a placebo arm and relied on cervical disease as the primary endpoints [5], [6], [7]. The Gardasil®9 trial used the previously licensed Gardasil® vaccine as the control arm [8]. For the 4 HPV types targeted by both vaccines, the primary endpoint was non-inferiority in antibody response, while cervical disease endpoints were used for the 5 additional types in Gardasil®9. All the vaccine trials have demonstrated outstanding long-term efficacy. This remarkable vaccine efficacy is now starting to be seen as effectiveness at the population level following introduction of HPV vaccines into national immunization programs [9].
All three vaccines are based on non-infectious recombinant type-specific L1 capsid proteins assembled into viral-like particles (VLPs) as immunogens. The expressed recombinant L1 capsids self-assemble in arrays of 72 pentamers that present an exterior surface closely mimicking HPV virions and it is this multiplicity of L1 domains that bestows the VLP antigen with significant immunogenicity, even in the absence of concomitant immune modulators (adjuvants) [10], [11].
The vaccines differ in the antigen expression system used, antigen composition and adjuvants included (Table 1) [12], [13], [14]. Both Gardasil® and Gardasil®9 products are produced in yeast and formulated with amorphous aluminum hydroxyphosphate sulfate (AAHS) adjuvant, which has an increased capacity to bind to L1 VLPs compared with other aluminum salts [15]. In contrast, Cervarix® is produced in insect cells using a baculovirus expression vector system and adjuvanted with AS04 which contains aluminum hydroxide plus an additional immunostimulant, the toll-like receptor 4 agonist monophosphoryl lipid A [16]. AS04 has been shown to enhance innate as well as humoral and cell-mediated immune responses [17], and may be responsible for differences in the overall immunogenicity described in head-to-head studies of the two vaccines [18], [19], [20], [21]. Other differences between the vaccines include the concentration of each of the L1 VLPs, and the ratio of antigen to adjuvant. Gardasil® has two-fold higher concentrations of HPV-16 L1 VLP and an equal concentration of HPV-18 L1 VLP compared with Cervarix®. Gardasil®9 contains twice the amount of HPV-18 L1 VLP, 50% more HPV-16 antigen and more than twice the level of adjuvant contained in Gardasil®.
Main characteristics of the licensed HPV prophylactic vaccines.
Cervarix®
Gardasil®
Gardasil9®
Manufacturer
GlaxoSmithKline
Merck and Co, Inc.
Merck and Co, Inc.
VLP Types Included
HPV-16/18
HPV-6/11/16/18
HPV-6/11/16/18/31/33/45/52/58
Dose of L1 VLP (μg)
20/20
20/40/40/20
30/40/60/40/20/20/20/20/20
Expression system
Trichoplusia ni (Hi 5) insect cell line infected with L1 recombinant baculovirus
Saccharomyces cerevisiae expressing L1
Saccharomyces cerevisiae expressing L1
Adjuvant
500 μg aluminum hydroxide salt and 50 μg 3-O- Desacyl-4′-monophosphoryl lipid (MPL) A
The vaccines were originally licensed for use as a three-dose regimen, administered intramuscularly. The licensed HPV vaccines have demonstrated remarkable efficacy in phase III clinical trials in HPV-naïve young women, providing nearly complete protection against incident infection and cervical disease caused by the HPV types that they specifically target [5], [6], [7], [8], [22]. This is coincident with the induction of a high level, high affinity polyclonal anti-L1 IgG antibody response to the HPV types included in the vaccine, and essentially 100% seroconversion to all targeted HPV types [23], [24], [25], [26], [27], [28]. The robust immunogenicity of the HPV vaccines contrasts with the immune responses observed after natural infection, in which seroconversion is found in only a proportion of individuals following incident infection [29]. Vaccine antibodies persist for several years after vaccination at levels that are orders of magnitude higher than those observed in natural infection [24], [30], [31], [32]. Antibodies generated during natural infection do not appear to consistently protect against subsequent infection. In addition, some studies suggest that protection may be limited to individuals with relatively high levels of naturally-acquired antibody [33], [34]. These findings are consistent with a recent study indicating that antibodies cloned from naturally elicited memory B cells were generally non-neutralizing while those isolated after vaccination had strong neutralization activity [35].
A degree of efficacy against some non-vaccine types (i.e. cross-protection) has been demonstrated in vaccine trials, particularly for HPV-31 and HPV-45 [36], [37]. Cervarix® appears to confer greater cross-protection than Gardasil® and this difference is reflected in antibody levels against these non-vaccine types [38]. For the purposes of this review, however, only antibody responses against vaccine-targeted types are considered.
Correlates of protection against infection afforded by HPV vaccines have not been formally identified and are difficult to study because of the exceptional efficacy of the vaccines. There have been very few cases of breakthrough infection or disease with the current vaccines to identify the threshold of antibody level that confers immunity among vaccinated subjects. Most studies attempting to address this question have analyzed the protective levels of naturally acquired antibodies in the placebo arm of vaccine trials [33], [34] or in cohort studies of infection [29]. Evaluation of different immunogenicity measures in reduced dose schedule trials, in which virological failures may be more likely to occur, could make it possible to establish immune correlates of protection.
Immunogenicity testing of prophylactic HPV vaccines in clinical trials has focused primarily on antibody responses because neutralizing antibodies are thought to be the principal effectors of protection against HPV infection. This is primarily based on experimental evidence in animal models demonstrating that protection against papillomavirus infection can be passively transferred in serum or purified immunoglobulin (Ig) G from VLP-vaccinated animals [39]. It has also been shown that very low levels of HPV antibodies are able to neutralize HPV-16; the 50% inhibitory concentration being estimated to range from 1.9 picomolar to 5.4 nM for three monoclonal antibodies [40]. Vaccine-induced antibodies against vaccine types are detectable not only in serum but also at mucosal sites of infection, such as the cervix and oral cavity [41], [42], [43], [44]. These antibodies are believed to reach the site of infection through transudation from serum and by exudation at sites of potential trauma that expose the basement membrane to infection [43], [45].
Review of immunogenicity of licensed HPV vaccines and duration of responsesImmunogenicity of three-dose schedules
A number of recent publications have thoroughly reviewed the immunogenicity and efficacy of licensed HPV vaccines in the context of the standard three-dose and reduced dose regimens [46], [47]. While all three licensed vaccines have similar efficacy against HPV infection and precancer lesions in clinical trials, the products do differ in immunogenicity, as demonstrated in a variety of assays. Head-to-head trials of three doses of Cervarix® and Gardasil® in 18–45 year-old women and in 12–15 year-old girls have found that HPV-16 antibody levels were significantly lower for Gardasil® when compared with Cervarix® [19], [20], [21], [48], although they had similar patterns of peak and decay over time. HPV-18 antibody levels and seropositivity were significantly lower for Gardasil® than Cervarix®. Furthermore, Gardasil® induced lower HPV-16 and HPV-18 specific CD4+ T cell responses, as well as lower memory B cell responses, particularly for HPV-18 up to 24 months after vaccination [19], [20], [21].
High and durable HPV-16 and HPV-18 antibody levels, significantly above natural infection levels, have been reported after vaccination with Cervarix® for at least 9.4 years [30]. Stable HPV-16 antibody levels, above natural infection levels were described for Gardasil® for at least 9 years [24]. However, HPV-18 antibody levels appear to decline to levels closer to natural infection. The observed seropositivity for HPV-18 is assay dependent (See Section 3) and was found to be 91% with a total IgG binding Luminex immunoassay and 60% with competitive Luminex immunoassays (cLIA) in women 9 years after vaccination.
Gardasil®9 has been reported to elicit comparable HPV-16 and HPV-18 antibody responses as Gardasil®. HPV-18 antibody levels induced by three doses of Gardasil®9 measured with the cLIA also declined over time and 78% seropositivity was observed 5 years after vaccination [49]. A similar decline in HPV-45 seropositivity was described, while antibody seropositivity for other types was maintained.
Covariates of immunogenicity have been evaluated both for Gardasil® and Gardasil®9 in three dose recipients [50], [51]. Age at the time of immunization was inversely correlated with antibody levels at month 7 for all the 9 HPV types. For all 9 HPV types, vaccine-induced antibody levels were higher in girls and boys than in young women. Boys had slightly higher HPV antibody levels than girls of the same age. Overall, immunogenicity was generally comparable across different races and different geographical regions. Small differences in month 7 HPV antibody levels were observed in 16–26 year-old women of different races. Black women had slightly higher HPV antibody levels than Asian or white women or women of other races. Individuals in Africa, Latin America and North America tended to have higher HPV antibody levels than those in Asia, and Europe. In addition, pre-existing HPV antibodies at the time of vaccination resulted in higher HPV responses to that type.
Critical questions that will need to be addressed by ongoing and planned trials include whether higher vaccine-induced antibody levels would predict longer duration of protection and how to improve sensitivity and specificity of antibody assays so that reliable correlations can be made between protection against infection and detection of antibodies.
Immunogenicity of reduced dose schedules
Clinical studies evaluating reduced dose schedules and the interval between doses for both vaccines have demonstrated non-inferior antibody responses in girls younger than 15 years of age that received two doses, given six months apart, when compared with women who received the standard three doses of vaccine and had evidence of efficacy in clinical trials [52], [53], [54]. These findings have led to the recommendations and approval of two-dose schedules in 9–14 year-old girls [55]. Both Cervarix® and Gardasil® induced similar antibody levels following two and three vaccine doses, for their corresponding vaccine, when the doses were administered six months apart, in 18–25 year-old women as well as in 10–18 year-old girls, over 4 years of follow-up [56], [57]. Administration of two doses of Cervarix® 1 month apart resulted in lower antibody levels than two doses (given 6 months apart) or three doses, but they were stable over a 4 year follow-up. Increasing the interval to one year between the two doses of Gardasil® in 11–13 year-old girls has demonstrated similar levels of HPV-16 and HPV-18 antibodies to those observed in a three-dose Gardasil® regimen, one year after vaccination [58], [59].
A head-to-head trial of two doses of Cervarix® or Gardasil® six months apart in 9–14 year-old girls demonstrated higher antibody levels for Cervarix® than Gardasil® at one year following initial vaccination [60]. Two doses of Cervarix® also induced higher antibody levels than three doses of Gardasil®. These studies have demonstrated that dosing interval is an important determinant of immunogenicity.
Immunogenicity data for a single vaccine dose are limited and to date has been examined in clinical trial participants who did not complete protocol or in trials that ended prematurely. Although lower than the levels induced by two- and three-dose schedules, a single dose of Cervarix®, in 18–25 year-old women from the NCI-sponsored Costa Rican Vaccine Trial, induced detectable HPV-16 and HPV-18 ELISA antibody levels in all participants. These remained approximately 9-fold and 5-fold higher than natural infection levels, respectively, 4 years after initial vaccination [56]. In a Gardasil® trial in adolescents in India that was ended prematurely, only a fraction of recipients had HPV-16 and HPV-18 seropositive responses following one-dose vaccination as assessed with multiplex bead assays (49% and 58%, respectively) twelve months post-vaccination, with levels around the assay seropositivity cut-off, but these were reported as stable over a 36 month follow-up [57]. These preliminary data suggest that one dose of HPV vaccine may be sufficient to confer protective immunity against HPV. The clinical trials being conducted in Costa Rica (ClinicalTrials.gov Identifier: NCT03180034) and Tanzania (ClinicalTrials.gov Identifier: NCT02834637) will provide opportunities for a comprehensive head-to-head comparison of immune responses induced by Cervarix® and Gardasil®9, in the context of one- and two-dose regimens in young adolescents.
With the increasing number of trials relying on immunogenicity data to support new vaccine recommendations, evaluation of one-dose trials, and approval of new follow-on vaccines, there is a need for the critical assessment of the sensitivity, specificity, reproducibility and comparability of HPV immunogenicity assays. These assays are briefly described in the next section along with the role for International Standards and steps being taken to address gaps in availability of these key reagents.
HPV vaccine immunogenicity assays and considerations for single dose studies
Measures of the type-specific immune response to HPV after vaccination include both cellular as well as humoral markers. The HPV vaccines induce potent T and B cell responses both in animal models and in humans [61]. However, most attention has focused on the humoral responses given the proposed role that neutralizing antibodies have in protection against infection and subsequent disease [62]. Serology assays include those detecting antibodies (neutralizing assays and binding assays), as well as those measuring antibody binding strength (avidity). The cellular assays include assays for evaluation of T cell (CD4 and CD8 T cell responses) and of memory B cell responses. The remainder of this review will focus on the most commonly used serology assays in vaccine trials.
Three main serological assays have been used to evaluate HPV L1 VLP antibody responses to HPV L1 VLP vaccines in clinical trials (Fig. 1): (1) pseudovirus-neutralization assays [63], (2) competitive (epitope-specific) immunoassays [64], [65], [66], and (3) VLP-IgG binding assays [67]. Neutralization assays are considered the most relevant for measuring the biological activity of the antibodies and the WHO has suggested that such assays should be considered the reference standard for assessing protective antibodies induced by the vaccines [68]. Competitive immunoassays, such as the cLIA, estimate neutralizing activity by measuring competition of test serum with neutralizing monoclonal antibodies. In contrast, ELISAs detect all antibodies, regardless of neutralization ability. Most L1 VLP ELISAs detect IgG, but other immunoglobulin classes (such as IgA) or IgG subclasses can be targeted if the specificity of the secondary antibody is changed. The glutathione S-transferase (GST) fusion L1 immunoassays are similar to L1 VLP ELISAs in that they detect all binding antibodies of particular immunoglobulin class that is determined by the secondary antibody. However, GST fusion assays rely on an L1 protein target that is synthesized in bacteria and is not assembled into conformational VLPs [69]. The results of these assays generally correlate well, particularly in specimens with high antibody levels, suggesting that the dominant immune response to HPV vaccination is IgG against neutralizing epitopes [42], [67], [70], [71], [72], [73], [74].
Three main types of assays have been used in the evaluation of antibody responses to HPV vaccines. (A) Neutralization assays, (B) Competitive immunoassays and (C) ELISA.
The neutralization assays measure total immunoglobulins (IgM, IgA, and IgG) that exhibit in vitro neutralizing function (Fig. 1A). This assay, originally developed by Dr. Schiller’s laboratory at the National Institutes of Health [63], has been widely adopted. The assay makes use of pseudovirions that incorporate the minor (L2) capsid protein, as well as the L1 protein and an encapsidated reporter gene, such as secreted alkaline phosphatase (SEAP) or luciferase [63], [75], [76], [77], [78]. Following pseudovirion binding to and entry into target cells, the reporter plasmid is translocated to the nucleus and expressed. When neutralizing antibodies are present, pseudovirus infection is blocked with a concomitant reduction in reporter signal. Antibody levels are generally expressed as the reciprocal of the sample dilution resulting in an a priori level of inhibition (usually 50%). Since they are cell-based, neutralization assays tend to have a higher coefficient of variation than binding assays, are labor intensive, and costly. Generally, these have been difficult to adapt to a high-throughput format, although a 384-well format has been described [78]. Most formats of the assay are not amenable to multiplexing, but a recent report achieved a three-plex assay using three different reporter genes expressing different fluorescent proteins [77].
The cLIA assay requires labeled type-specific monoclonal antibodies and conformationally intact VLPs (Fig. 1B). Antibodies in the serum sample bind to VLPs and prevent binding of the labeled monoclonal antibody, thereby reducing signal. Concentrations are generally based on a standard curve. The assay measures antibodies of all immunoglobulin classes but, in principle, only to one epitope. Thus, it has high specificity, but results may underestimate the total functional antibody levels. The assay is epitope specific, rapid, readily multiplexed and amenable to high-throughput platforms. Vaccine trials sponsored by Merck used a competitive multiplex bead array assay [65], [66].
ELISAs also require conformationally intact VLPs and they measure both neutralizing and non-neutralizing antibodies, recognizing both conformational and non-conformational epitopes (Fig. 1C). VLPs are bound to a solid surface (beads or wells) and antibodies in the sample bind directly. Bound antibody is detected with labeled secondary antibodies directed against a specific Ig class, usually anti-IgG. The label can be an enzyme, an affinity label or a fluorescent molecule. L1 VLP ELISAs for type-specific IgGs have been used by GlaxoSmithKline and several research labs as the main assay in a number of immunogenicity trials [19], [20], [21], [56], [67], [79]. ELISAs for many other targets have been widely used, so the format is familiar to laboratories. The format is adaptable to multiplexing with bead arrays [70], [72], [80] or multi-spot wells [73], fast and amenable to high-throughput testing. However, only one immunoglobulin class is detected at a time and both neutralizing and non-neutralizing antibodies will generate a signal.
The overall advantages and disadvantages of the three broad classes of serology assays are summarized in Table 2. Both qualitative (positive/negative) and quantitative results (magnitude of antibody levels) are important. The quality of all these assays is dependent on the quality of the VLPs, pseudovirions and QC procedures [68]. Validated critical reagents and assay standards are not available commercially and therefore must be prepared and validated by the laboratory. Strict adherence to standard operating procedures for production and quality control of these reagents is required, monitoring purity, concentration and type-specific conformation for each lot. When the immunogenicity of two different vaccine formulations is being compared, the use of VLP antigens produced in an expression system that is different from that used to produce the vaccines would be preferable to avoid potentially favoring one formulation over another [18], [21]. Assay reproducibility should be monitored with the use of high- and low-antibody titer control sera in every run and trends monitored. Cut-off values can be challenging to determine, and although most laboratories base the value using a panel of virginal sera, such as children’s sera, there are critical differences between cut-off determinations used in different laboratories and assays. Currently there are no guidelines on methods to establish serostatus cut-offs which has a major influence on seropositivity rates. Therefore, establishing uniform criteria for cut-off determinations of seropositivity will be particularly critical for one-dose trials where lower levels of antibodies are anticipated.
Three main assay types used in monitoring HPV vaccine immunogenicity and their advantages and disadvantages.
Advantages
Disadvantages
Neutralization assay
Measures function closest to presumed mechanism of protection
All immunoglobulin classes are detected
Requires pseudovirions for each type
Requires cell culture and time for cells to grow
Time-consuming and labor intensive
Limited ability to multiplex
Higher coefficients of variation
Competitive immunoassay
Detects neutralizing antibodies
Easily multiplexed with bead arrays (e.g. Luminex)
Rapid, high throughput
All immunoglobulin classes detected
Only a subset of total neutralizing antibodies detected
Mulitplexing requires compromise between selecting dominant epitope and retaining type specificity
Enzyme linked immunosorbent assay
Fast, high throughput
Familiar assay format
Amenable to multiplexing (bead arrays or multispot wells)
Detects one immunoglobulin class (IgG or IgA), determined by secondary antibody
Non-neutralizing binding antibodies can be detected
Because different laboratories have used different assays for evaluation of immunogenicity to the HPV vaccines and key reagents are prepared differently in each laboratory, inter-laboratory assay standardization has been quite challenging. In 2006, the Bill and Melinda Gates Foundation funded a WHO Global HPV Laboratory Network whose main activities were to work out systems for international comparability of HPV ELISA assays for HPV-16 and HPV-18 [81], [82], [83]. A series of international collaborative studies proved the basic principles of comparability [82], [83], [84]. The serology assays in use were found to generate sufficiently similar results, such that a simple use of the same international reference standard in all laboratories gave highly comparable data [83]. Such reference sera are formally established as International Standards (IS) that define the International Unit (IU) of HPV antibodies and can be ordered from the National Institute of Biological Standards and Controls (NIBSC, Potters Bar, UK). A simple mathematical calculation called the parallel line method can be used to compare the crude results from a dilution series of the serum to be tested with the reference serum to find the antibody level [83]. Ideally, serology assay results should be reported in IU to facilitate direct comparison of results. The laboratory step-by-step protocol for HPV-16 and HPV-18 assays is published in the WHO HPV Laboratory Manual, which also details the protocols of two common serology methods found to be robust and transferable (the pseudovirion neutralization assay and the VLP ELISA assay) [68].
In addition to concentrations, antibody quality can be evaluated in terms of binding strength of antibodies to VLPs, or avidity. Only a few studies have examined avidity in samples from HPV vaccine trials [18], [57], [85], [86]. Avidity assays use the ELISA format but add a dissociating step with chaotropic agents such as ammonium thiocyanate, sodium thiocyanate or guanidine hydrochloride. Generally, the ratio of antibodies detected after dissociation to those detected without dissociation is used to calculate an avidity index. Care must be taken when selecting chaotropic agents and concentrations to ensure that the dissociation step does not introduce significant conformational change to the VLPs. Several assay variations have been reported [87], [88], [89], [90] but no standard avidity assay or interlaboratory comparisons have been performed to date. Affinity maturation and increases in avidity have been shown with increasing doses and time following vaccination [18], [57], [89], [90]. Although lower than that observed in three-dose recipients, high avidity levels indicative of antibody affinity maturation have been observed in one-dose recipients of Cervarix® and Gardasil® [57], [85]. The importance of antibody avidity in antiviral protection has been shown experimentally for some viruses, however, the significance of avidity in protection against HPV infection is not yet known [91]. In low antibody level situations, such as may be encountered with one-dose schedules, this could be an important parameter to monitor.
Robust and standardized serological assays are critical for current and future HPV vaccine evaluation and may help identify immune correlate(s) of protection and provide early indications of potential efficacy of new vaccine products, such as biosimilars. For closely related vaccines, immunogenicity data may support regulatory approval, accelerating vaccine implementation.
Based on long-term efficacy data, HPV vaccines are expected to induce sufficiently high levels of immunity to protect against infection and subsequent disease. However, low levels of antibodies are expected to be induced by single dose regimens, in particularly for HPV-18 in Gardasil® and Gardasil®9 recipients as well as for HPV-45 in Gardasil®9 recipients, based on long-term antibody persistence data and the data published in reduced dose schedules [19], [49], [92], [93]. Thus, efforts to increase serology assay sensitivity at the lower end may be required to support immunobridging trials for single dose vaccines. Results from mouse intravaginal challenge systems suggest that the levels required for in vivo protection are estimated to be orders of magnitude lower than levels detected in vitro by ELISA or neutralization assays [75], [94], suggesting that strategies for improvement in detectability of HPV antibody responses in vitro to match in vivo protection are warranted.
It is clear that immunogenicity assessment in one-dose vaccine studies will be challenging. The importance of the immunologic data from these trials requires that the data from these assays be reliable and interpretable. This means that testing must be done with methods that allow reporting results in terms of directly comparable International Units. International Standards are still required for the additional 5 oncogenic types included in Gardasil®9. A newly launched HPV Serology Standardization project, co-funded by the Bill and Melinda Gates foundation and the US National Cancer Institute, is addressing critical needs for global harmonization of HPV serology testing in clinical trials of HPV prophylactic vaccines. The project plans to identify additional secondary standards for the types included in current vaccines, provide critical reference reagents (VLPs), and develop testing guidelines, all of which will be made available to the HPV serology community. This builds on previous efforts of the WHO HPV LabNet and will be done in parallel with ongoing WHO and NIBSC efforts for production of International Standards for the additional HPV types included in Gardasil®9.
ReferencesMcCormackP.L.JouraE.A.Spotlight on quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine(Gardasil®) in the prevention of premalignant genital lesions, genital cancer, and genital warts in womenBioDrugs25201133934321942919McKeageK.RomanowskiB.Spotlight on AS04-adjuvanted human papillomavirus (HPV) types 16 and 18 vaccine (Cervarix®)BioDrugs25201126526921815703LopalcoP.L.Spotlight on the 9-valent HPV vaccineDrug Des Devel Ther1120173544PetroskyE.BocchiniJ.A.Jr.HaririS.ChessonH.CurtisC.R.SaraiyaM.Use of 9-valent human papillomavirus (HPV) vaccine: updated HPV vaccination recommendations of the advisory committee on immunization practicesMMWR Morb Mortal Wkly Rep64201530030425811679FUTURE II Study GroupQuadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesionsNew Engl J Med35620071915192717494925PaavonenJ.JenkinsD.BoschF.X.NaudP.SalmeronJ.WheelerC.M.Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trialLancet36920072161217017602732GarlandS.M.Hernandez-AvilaM.WheelerC.M.PerezG.HarperD.M.LeodolterS.Quadrivalent vaccine against human papillomavirus to prevent anogenital diseasesNew Engl J Med35620071928194317494926JouraE.A.GiulianoA.R.IversenO.E.BouchardC.MaoC.MehlsenJ.A 9-valent HPV vaccine against infection and intraepithelial neoplasia in womenNew Engl J Med372201571172325693011DroletM.BenardE.BoilyM.C.AliH.BaandrupL.BauerH.Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysisLancet Infect Dis15201556558025744474HarroC.D.PangY.Y.RodenR.B.HildesheimA.WangZ.ReynoldsM.J.Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccineJ Natl Cancer Inst93200128429211181775PintoL.A.EdwardsJ.CastleP.E.HarroC.D.LowyD.R.SchillerJ.T.Cellular immune responses to human papillomavirus (HPV)-16 L1 in healthy volunteers immunized with recombinant HPV-16 L1 virus-like particlesJ Infect Dis188200332733812854090Food and Drug Administration. Highlights of prescribing information. Gardasil [Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant]; 2006. Available at: https://www.fda.gov/downloads/biologicsbloodvaccines/vaccines/approvedproducts/ucm111263.pdf [accessed on Aug 16 2017].Food and Drug Administration. Highlights of prescribing information. Cervarix [human papillomavirus bivalent (types 16, 18) vaccine, recombinant]; 2009. Available at: https://www.fda.gov/downloads/biologicsbloodvaccines/vaccines/approvedproducts/ucm186981.pdf [accessed on Aug 16 2017].Food and Drug Administration. Highlights of prescribing information. Gardasil 9 (human papillomavirus 9-valent vaccine, recombinant); 2014. Available at: https://www.fda.gov/downloads/biologicsbloodvaccines/vaccines/approvedproducts/ucm426457.pdf [accessed on Aug 16 2017].CaulfieldM.J.ShiL.WangS.WangB.ToberyT.W.MachH.Effect of alternative aluminum adjuvants on the absorption and immunogenicity of HPV16 L1 VLPs in miceHuman Vacc32007139145GianniniS.L.HanonE.MorisP.Van MechelenM.MorelS.DessyF.Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt onlyVaccine2420065937594916828940GarconN.WettendorffM.Van MechelenM.Role of AS04 in human papillomavirus vaccine: mode of action and clinical profileExpert Opin Biol Ther11201166767721457083HerrinD.M.CoatesE.E.CostnerP.J.KempT.J.NasonM.C.SahariaK.K.Comparison of adaptive and innate immune responses induced by licensed vaccines for Human PapillomavirusHum Vaccin Immunother1020143446345425483691EinsteinM.H.LevinM.J.ChatterjeeA.ChakhtouraN.TakacsP.CatteauG.Comparative humoral and cellular immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women aged 18–45 years: follow-up through Month 48 in a Phase III randomized studyHum Vaccin Immunother1020143455345625483700EinsteinM.H.TakacsP.ChatterjeeA.SperlingR.S.ChakhtouraN.BlatterM.M.Comparison of long-term immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women aged 18–45 years: end-of-study analysis of a Phase III randomized trialHum Vaccin Immunother1020143435344525483701EinsteinM.H.BaronM.LevinM.J.ChatterjeeA.FoxB.ScholarS.Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 vaccine and HPV-6/11/16/18 vaccine: follow-up from months 12–24 in a Phase III randomized study of healthy women aged 18–45 yearsHuman Vaccin7201113431358KreimerA.R.GonzalezP.KatkiH.A.PorrasC.SchiffmanM.RodriguezA.C.Efficacy of a bivalent HPV 16/18 vaccine against anal HPV 16/18 infection among young women: a nested analysis within the Costa Rica Vaccine TrialLancet Oncol12201186287021865087MunozN.ManalastasR.Jr.PitisuttithumP.TresukosolD.MonsonegoJ.AultK.Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24–45 years: a randomised, double-blind trialLancet37320091949195719493565NygardM.SaahA.MunkC.TryggvadottirL.EnerlyE.HortlundM.Evaluation of the long-term anti-human papillomavirus 6 (HPV6), 11, 16, and 18 immune responses generated by the quadrivalent HPV vaccineClin Vaccine Immunol22201594394826084514OlssonS.E.KjaerS.K.SigurdssonK.IversenO.E.Hernandez-AvilaM.WheelerC.M.Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infectionHuman Vaccin52009696704RomanowskiB.SchwarzT.F.FergusonL.PetersK.DionneM.BehreU.Sustained immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine administered as a two-dose schedule in adolescent girls: five-year clinical data and modeling predictions from a randomized studyHum Vaccin Immunother122016202926176261SchwarzT.F.HuangL.M.MedinaD.M.ValenciaA.LinT.Y.BehreU.Four-year follow-up of the immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine when administered to adolescent girls aged 10–14 yearsJ Adolesc Health50201218719422265115VillaL.L.AultK.A.GiulianoA.R.CostaR.L.PettaC.A.AndradeR.P.Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18Vaccine2420065571558316753240BeachlerD.C.JenkinsG.SafaeianM.KreimerA.R.WentzensenN.Natural acquired immunity against subsequent genital human papillomavirus infection: a systematic review and meta-analysisJ Infect Dis21320161444145426690341NaudP.S.Roteli-MartinsC.M.De CarvalhoN.S.TeixeiraJ.C.de BorbaP.C.SanchezN.Sustained efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine: final analysis of a long-term follow-up study up to 9.4 years post-vaccinationHum Vaccin Immunother1020142147216225424918FerrisD.SamakosesR.BlockS.L.Lazcano-PonceE.RestrepoJ.A.ReisingerK.S.Long-term study of a quadrivalent human papillomavirus vaccinePediatrics1342014e657e66525136050Roteli-MartinsC.M.NaudP.De BorbaP.TeixeiraJ.C.De CarvalhoN.S.ZahafT.Sustained immunogenicity and efficacy of the HPV-16/18 AS04-adjuvanted vaccine: up to 8.4 years of follow-upHum Vaccin Immunother8201239039722327492SafaeianM.PorrasC.SchiffmanM.RodriguezA.C.WacholderS.GonzalezP.Epidemiological study of anti-HPV16/18 seropositivity and subsequent risk of HPV16 and -18 infectionsJ Natl Cancer Inst10220101653166220944077CastellsagueX.NaudP.ChowS.N.WheelerC.M.GermarM.J.LehtinenM.Risk of newly detected infections and cervical abnormalities in women seropositive for naturally acquired human papillomavirus type 16/18 antibodies: analysis of the control arm of PATRICIAJ Infect Dis210201451753424610876SchererE.M.SmithR.A.GallegoD.F.CarterJ.J.WipfG.C.HoyosM.A single human papillomavirus vaccine dose improves B cell memory in previously infected subjectsEBioMedicine102016556427423190WheelerC.M.KjaerS.K.SigurdssonK.IversenO.E.Hernandez-AvilaM.PerezG.The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16–26 yearsJ Infect Dis199200993694419236277PaavonenJ.NaudP.SalmeronJ.WheelerC.M.ChowS.N.ApterD.Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young womenLancet374200930131419586656BissettS.L.GodiA.JitM.BeddowsS.Seropositivity to non-vaccine incorporated genotypes induced by the bivalent and quadrivalent HPV vaccines: a systematic review and meta-analysisVaccine3520173922392928633892BreitburdF.KirnbauerR.HubbertN.L.NonnenmacherB.Trin-Dinh-DesmarquetC.OrthG.Immunization with viruslike particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infectionJ Virol691995395939637745754DayP.M.ThompsonC.D.BuckC.B.PangY.Y.LowyD.R.SchillerJ.T.Neutralization of human papillomavirus with monoclonal antibodies reveals different mechanisms of inhibitionJ Virol8120078784879217553881PintoL.A.KempT.J.TorresB.N.Isaacs-SorianoK.InglesD.AbrahamsenM.Quadrivalent human papillomavirus (HPV) vaccine induces HPV-specific antibodies in the oral cavity: results from the mid-adult male vaccine trialJ Infect Dis21420161276128327511896KempT.J.Garcia-PineresA.FalkR.T.PonceletS.DessyF.GianniniS.L.Evaluation of systemic and mucosal anti-HPV16 and anti-HPV18 antibody responses from vaccinated womenVaccine2620083608361618541349Nardelli-HaefligerD.WirthnerD.SchillerJ.T.LowyD.R.HildesheimA.PonciF.Specific antibody levels at the cervix during the menstrual cycle of women vaccinated with human papillomavirus 16 virus-like particlesJ Natl Cancer Inst9520031128113712902442PetajaT.PedersenC.PoderA.StraussG.CatteauG.ThomasF.Long-term persistence of systemic and mucosal immune response to HPV-16/18 AS04-adjuvanted vaccine in preteen/adolescent girls and young womenInt J Cancer12920112147215721190190LongetS.SchillerJ.T.BobstM.JichlinskiP.Nardelli-HaefligerD.A murine genital-challenge model is a sensitive measure of protective antibodies against human papillomavirus infectionJ Virol852011132531325921976653StanleyM.A.SudengaS.L.GiulianoA.R.Alternative dosage schedules with HPV virus-like particle vaccinesExp Rev Vacc13201410271038TohZ.Q.LicciardiP.V.FongJ.GarlandS.M.TabriziS.N.RussellF.M.Reduced dose human papillomavirus vaccination: an update of the current state-of-the-artVaccine3320155042505026271829DraperE.BissettS.L.Howell-JonesR.WaightP.SoldanK.JitM.A randomized, observer-blinded immunogenicity trial of Cervarix® and Gardasil® human papillomavirus vaccines in 12–15 year old girlsPLoS One82013e6182523650505GuevaraA.CabelloR.WoelberL.Duarte Moreira JrE.JouraE.A.ReichO.Antibody persistence and evidence of immune memory at 5 years following administration of the 9-valent HPV vaccineVaccine3520175050505728789851PetersenL.K.RestrepoJ.MoreiraE.D.Jr.IversenO.E.PitisuttithumP.Van DammeP.Impact of baseline covariates on the immunogenicity of the 9-valent HPV vaccine – a combined analysis of five phase III clinical trialsPapillomavirus Res3201710511528720442GiulianoA.R.Lazcano-PonceE.VillaL.NolanT.MarchantC.RadleyD.Impact of baseline covariates on the immunogenicity of a quadrivalent (types 6, 11, 16, and 18) human papillomavirus virus-like-particle vaccineJ Infect Dis19620071153116217955433IversenO.E.MirandaM.J.UliedA.SoerdalT.LazarusE.ChokephaibulkitK.Immunogenicity of the 9-valent HPV vaccine using 2-dose regimens in girls and boys vs a 3-dose regimen in womenJAMA31620162411242127893068DobsonM.McNeilS.DionneM.DawarM.OlgivieG.Immunogenicity of 2 doses of HPV vaccine in younger adolescents in young womenJAMA30920131793180223632723RomanowskiB.SchwarzT.FergusonL.FergusonM.Immune response to the HPV-16/18 ASO4-adjuvanted vaccine administered as a 2-dose or 3-dose schedule up to 4 years after vaccination: Results from a randomized studyHum Vaccin Immunother10201311551165MeitesE.KempeA.MarkowitzL.E.Use of a 2-dose schedule for human papillomavirus vaccination – updated recommendations of the advisory committee on immunization practicesMMWR6520161405140827977643SafaeianM.PorrasC.PanY.KreimerA.SchillerJ.T.GonzalezP.Durable antibody responses following one dose of the bivalent human papillomavirus L1 virus-like particle vaccine in the Costa Rica Vaccine TrialCancer Prev Res (Phila)620131242125024189371SankaranarayananR.PrabhuP.R.PawlitaM.GheitT.BhatlaN.MuwongeR.Immunogenicity and HPV infection after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre prospective cohort studyLancet Oncol172016677726652797NeuzilK.M.CanhD.G.ThiemV.D.JanmohamedA.HuongV.M.TangY.Immunogenicity and reactogenicity of alternative schedules of HPV vaccine in Vietnam: a cluster randomized noninferiority trialJAMA30520111424143121486975LamontagneD.S.ThiemV.D.HuongV.M.TangY.NeuzilK.M.Immunogenicity of quadrivalent HPV vaccine among girls 11 to 13 years of age vaccinated using alternative dosing schedules: results 29 to 32 months after third doseJ Infect Dis20820131325133423901077LeungT.F.LiuA.P.LimF.S.ThollotF.OhH.M.LeeB.W.Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine administered according to 2- and 3-dose schedules in girls aged 9–14 years: Results to month 12 from a randomized trialHum Vaccin Immunother1120151689170226062002StanleyM.Immunobiology of HPV and HPV vaccinesGynecol Oncol1092008S15S2118474288SchillerJ.T.LowyD.R.Immunogenicity testing in human papillomavirus virus-like-particle vaccine trialsJ Infect Dis200200916617119519255PastranaD.V.BuckC.B.PangY.Y.ThompsonC.D.CastleP.E.FitzGeraldP.C.Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18Virology321200420521615051381DiasD.Van DorenJ.SchlottmannS.KellyS.PuchalskiD.RuizW.Optimization and validation of a multiplexed luminex assay to quantify antibodies to neutralizing epitopes on human papillomaviruses 6, 11, 16, and 18Clin Diagn Lab Immunol12200595996916085914OpalkaD.LachmanC.E.MacMullenS.A.JansenK.U.SmithJ.F.ChirmuleN.Simultaneous quantitation of antibodies to neutralizing epitopes on virus-like particles for human papillomavirus types 6, 11, 16, and 18 by a multiplexed luminex assayClin Diagn Lab Immunol10200310811512522048OpalkaD.MatysK.BojczukP.GreenT.GesserR.SaahA.Multiplexed serologic assay for nine anogenital human papillomavirus typesClin Vacc Immunol172010818827DessyF.J.GianniniS.L.BougeletC.A.KempT.J.DavidM.P.PonceletS.M.Correlation between direct ELISA, single epitope-based inhibition ELISA and pseudovirion-based neutralization assay for measuring anti-HPV-16 and anti-HPV-18 antibody response after vaccination with the AS04-adjuvanted HPV-16/18 cervical cancer vaccineHuman Vaccin42008425434World Health OrganizationHuman papillomavirus laboratory manual1st ed.2010SwitzerlandGenevaWaterboerT.SehrP.MichaelK.M.FranceschiS.NielandJ.D.JoosT.O.Multiplex human papillomavirus serology based on in situ-purified glutathione s-transferase fusion proteinsClin Chem5120051845185316099939FaustH.KnektP.ForslundO.DillnerJ.Validation of multiplexed human papillomavirus serology using pseudovirions bound to heparin-coated beadsJ Gen Virol9120101840184820181747RobbinsH.A.KempT.J.PorrasC.RodriguezA.C.SchiffmanM.WacholderS.Comparison of antibody responses to human papillomavirus vaccination as measured by three assaysFront Oncol3201432824455487RobbinsH.A.WaterboerT.PorrasC.KempT.J.PawlitaM.RodriguezA.C.Immunogenicity assessment of HPV16/18 vaccine using the glutathione S-transferase L1 multiplex serology assayHum Vaccin Immunother1020142965297425483632PanickerG.RajbhandariI.GurbaxaniB.M.QuerecT.D.UngerE.R.Development and evaluation of multiplexed immunoassay for detection of antibodies to HPV vaccine typesJ Immunol Methods417201510711425554636BrownD.MullerM.SehrP.PawlitaM.SeitzH.RubioI.Concordance assessment between a multiplexed competitive Luminex immunoassay, a multiplexed IgG Luminex immunoassay, and a pseudovirion-based neutralization assay for detection of human papillomaviruse types 16 and 18Vaccine3220145880588725148777SchillerJ.T.LowyD.R.Understanding and learning from the success of prophylactic human papillomavirus vaccinesNat Rev Microbiol10201268169222961341BuckC.B.PastranaD.V.LowyD.R.SchillerJ.T.Generation of HPV pseudovirions using transfection and their use in neutralization assaysMethods Mol Med119200544546216350417NieJ.LiuY.HuangW.WangY.Development of a triple-color pseudovirion-based assay to detect neutralizing antibodies against human papillomavirusViruses8201610727120611SehrP.RubioI.SeitzH.PutzkerK.Ribeiro-MullerL.PawlitaM.High-throughput pseudovirion-based neutralization assay for analysis of natural and vaccine-induced antibodies against human papillomavirusesPLoS One82013e7567724124504GodiA.BissettS.L.MillerE.BeddowsS.Relationship between humoral immune responses against HPV16, HPV18, HPV31 and HPV45 in 12–15 year old girls receiving Cervarix® or Gardasil® vaccinePLoS One102015e014092626495976ScherpenisseM.MollersM.ScheppR.M.BootH.J.de MelkerH.E.MeijerC.J.Seroprevalence of seven high-risk HPV types in the NetherlandsVaccine3020126686669322959981FergusonM.WilkinsonD.E.ZhouT.WHO meeting on the standardization of HPV assays and the role of the WHO HPV Laboratory Network in supporting vaccine introduction held on 24–25 January 2008, Geneva, SwitzerlandVaccine27200933734719007840EklundC.UngerE.R.Nardelli-HaefligerD.ZhouT.DillnerJ.International collaborative proficiency study of Human Papillomavirus type 16 serologyVaccine30201229429922079074FergusonM.HeathA.JohnesS.PagliusiS.DillnerJ.Results of the first WHO international collaborative study on the standardization of the detection of antibodies to human papillomavirusesInt J Cancer11820061508151416184553BissettS.L.WilkinsonD.TettmarK.I.JonesN.StanfordE.PanickerG.Human papillomavirus antibody reference reagents for use in postvaccination surveillance serologyClin Vacc Immunol192012449451SafaeianM.SampsonJ.N.PanY.PorrasC.KempT.GonzalezP.Durability of protection afforded by fewer doses of the HPV16/18 vaccine: the CVT trialJ Nat Canc Inst1102018djx158DonkenR.Schurink-Van't KloosterT.M.ScheppR.M.van der KlisF.R.KnolM.J.MeijerC.J.Immune responses after 2 versus 3 doses of HPV vaccination up to 4½ years after vaccination: An observational study among Dutch routinely vaccinated girlsJ Infect Dis215201735936628011916BradyA.M.UngerE.R.PanickerG.Description of a novel multiplex avidity assay for valuating HPV antibodiesJ Immunol Methods4472017313628433580DaunerJ.G.PanY.HildesheimA.KempT.J.PorrasC.PintoL.A.Development and application of a GuHCl-modified ELISA to measure the avidity of anti-HPV L1 VLP antibodies in vaccinated individualsMol Cell Probes262012738022285687KempT.J.SafaeianM.HildesheimA.PanY.PenroseK.J.PorrasC.Kinetic and HPV infection effects on cross-type neutralizing antibody and avidity responses induced by Cervarix®Vaccine31201216517023123024BoxusM.LockmanL.FochesatoM.LorinC.ThomasF.GianniniS.L.Antibody avidity measurements in recipients of Cervarix vaccine following a two-dose schedule or a three-dose scheduleVaccine3220143232323624731816BachmannM.F.KalinkeU.AlthageA.FreerG.BurkhartC.RoostH.The role of antibody concentration and avidity in antiviral protectionScience2761997202420279197261OlssonS.E.VillaL.L.CostaR.L.PettaC.A.AndradeR.P.MalmC.Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccineVaccine2520074931493917499406TohZ.Q.RussellF.M.ReyburnR.FongJ.TuivagaE.RatuT.Sustained antibody responses 6 years following 1, 2, or 3 doses of quadrivalent human papillomavirus (HPV) vaccine in adolescent Fijian gGirls, and subsequent responses to a single dose of bBivalent HPV vaccine: A prospective cohort studyClin Infect Dis64201785285928034886DayP.M.KinesR.C.ThompsonC.D.JaguS.RodenR.B.LowyD.R.In vivo mechanisms of vaccine-induced protection against HPV infectionCell Host Microbe8201026027020833377Acknowledgements
This project has been funded in whole or in part with federal funds from the National Cancer Institute, National Institutes of Health, under Contract No. HHSN261200800001E. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the US. Government.